ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice

• DOI: 10.1016/j.bcp.2017.06.119
• Publication Date: 2017-06-20T10:30:37Z
• Authors: Ammar Kurdi; Matthias Cleenewerck; Christel Vangestel; Sophie Lyssens; Wim Declercq; Jean-Pierre Timme...; Sigrid Stroobants; Koen Augustyns; Guido R.Y. De Meyer; Pieter Van Der Veken; Wim Martinet
• Keywords: Mice, Knockout; 0301 basic medicine; Autophagy-Related Proteins; Antineoplastic Agents; Forkhead Transcription Factors; Mice, Transgenic; Adenocarcinoma; Cysteine Proteinase Inhibitors; 3. Good health; Cysteine Endopeptidases; Jurkat Cells; 03 medical and health sciences; HEK293 Cells; Drug Stability; Drug Design; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Autophagy; Animals; Humans; HT29 Cells; Microtubule-Associated Proteins; Cell Proliferation

Autophagy is a cell survival mechanism hijacked by advanced tumors to endure a rough microenvironment. Late autophagy inhibitors such as (hydroxy)chloroquine have been used clinically to halt tumor progression with modest success. However, given the toxic nature of these compounds and their lack of specificity, novel targets should be considered. We recently identified a benzotropolone derivative that significantly inhibited the essential autophagy protein ATG4B. Therefore, we synthesized and tested additional benzotropolone compounds to identify a promising ATG4B inhibitor that impairs autophagy both in vitro and in vivo. A compound library containing 27 molecules with a benzotropolone backbone was synthesized and screened for inhibition of recombinant ATG4B. Depending on the benzotropolone compound, inhibition of recombinant ATG4B ranged from 3 to 82%. Active compounds were evaluated in cellular assays to confirm inhibition of ATG4B and suppression of autophagy. Seven compounds inhibited processing of the autophagy protein LC3 and autophagosome formation. Compound UAMC-2526 was selected for further in vivo use because of its fair plasma stability. This compound abolished autophagy both in nutrient-deprived GFP-LC3 mice and in CD1-/- Foxn1nu mice bearing HT29 colorectal tumor xenografts. Moreover, addition of UAMC-2526 to the chemotherapy drug oxaliplatin significantly improved inhibition of tumor growth. Our data indicate that suppression of autophagy via ATG4B inhibition is a feasible strategy to augment existing chemotherapy efficacy and to halt tumor progression.